The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
People at high risk for HIV acquisition should be offered pre-exposure prophylaxis (PrEP). Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is currently the only medication recommended for pre-exposure prophylaxis (PrEP) by the Centers for Disease Control and Prevention (CDC) in people at high risk for HIV acquisition. This article will review medications currently under investigation and the future landscape of PrEP therapy. Areas covered: This article will review clinical trials that have investigated nontraditional regimens of TDF/FTC, antiretroviral agents from different drug classes such as integrase strand transfer inhibitors (INSTI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) as potential PrEP therapies. Expert commentary: Currently, there are several investigational drugs in the pipeline for PrEP against HIV infection. Increased utilization of PrEP therapy depends on provider identification of people at high risk for HIV transmission. Advances in PrEP development will expand options and access for people and reduce the risk of HIV acquisition.
a School of Pharmacy and Health Sciences , Fairleigh Dickinson University , Florham Park , USA.
Ayşe Elif
AE
Özdener
b Touro College of Pharmacy , New York , NY , USA.|c Department of Pharmacy , State University of New York (SUNY) Downstate Medical Center , Brooklyn , NY , USA.
Tae Eun
TE
Park
a School of Pharmacy and Health Sciences , Fairleigh Dickinson University , Florham Park , USA.
Julie
J
Kalabalik
d Infectious Disease Care , Randolph , USA.
Rachna
R
Gupta
D000282:Administration, Intravaginal; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003274:Contraceptive Devices, Female; D004334:Drug Administration Schedule; D004338:Drug Combinations; D015507:Drugs, Investigational / Q000627:therapeutic use*; D000068679:Emtricitabine / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D065129:Pre-Exposure Prophylaxis / Q000379:methods*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000068698:Tenofovir / Q000627:therapeutic use
D019380:Anti-HIV Agents; D004338:Drug Combinations; D015507:Drugs, Investigational; D019428:HIV Integrase Inhibitors; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000068679:Emtricitabine
HIV; PrEP; Pre-exposure prophylaxis; antiretroviral; human immunodeficiency virus